10/6 2021

Lumen Bioscience awarded federal funding to advance Covid-19 antibody cocktail through Phase 2 Clinical Evaluation

2021-10-06T19:54:41+00:00October 6th, 2021|ATI in the News|

Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced new development funding from the US Army for its Covid-19 monoclonal antibody drug cocktail. The support is provided by the US Army Medical Research and Development Command (USAMRDC), operating through the Medical Technology Enterprise Consortium (MTEC).

10/1 2021

UAB to study hand-held device that monitors traumatic brain injury

2021-10-04T20:06:31+00:00October 1st, 2021|ATI in the News|

Researchers at the University of Alabama at Birmingham will investigate the usefulness of a new non-invasive method to measure the expansion of hematomas in the brain. This project is funded by the Combat Casualty Care Research Program’s Neurotrauma Program at the US Army Medical Research and Development Command via the Medical Technology Enterprise Consortium.

9/28 2021

Mitochon Pharmaceuticals and University of Kentucky Awarded MTEC Grant for MP-201 in Traumatic Brain Injury

2021-09-29T15:09:46+00:00September 28th, 2021|ATI in the News|

Mitochon Pharmaceuticals today is pleased to announce the receipt of a $500,000 grant in conjunction with the University of Kentucky for “Advancement of Drugs for the Treatment of Repeated Mild Traumatic Brain Injury (mTBI)” through a joint funded program by an Alzheimer’s Disease group, BrightFocus Foundation and a military focused foundation, Medical Technology Enterprise Consortium (MTEC).

9/8 2021

Astrocyte Pharmaceuticals Awarded Major Grant to Further Develop Promising Treatment for Brain Injury

2021-09-08T19:07:14+00:00September 8th, 2021|ATI in the News|

Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, announced today that it has received a $500,000 award jointly funded by the Medical Technology Enterprise Consortium (MTEC) and the BrightFocus Foundation.

8/17 2021

MTEC: Celebrating six years of serving those who serve our country

2021-08-17T12:57:48+00:00August 17th, 2021|Success Stories|

In celebration of the Medical Technology Enterprise Consortium's (MTEC) six-year anniversary, we're taking a look back at its considerable impact on the lives of our military personnel and veterans.

8/2 2021

Sense Neuro Diagnostics receives $2.43 Million from US Military to advance technology to diagnose and monitor traumatic brain injury (TBI) in a field environment

2021-08-02T14:57:32+00:00August 2nd, 2021|ATI in the News|

Sense Neuro Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, today announced its selection by the U.S. Army Medical Research and Development Command (USAMRDC) Combat Casualty Care Research Program to receive $2.43 million from the U.S. Department of Defense to advance technology to diagnose and monitor traumatic brain injury (TBI) in a field environment. The award was issued through Medical Technology Enterprise Consortium (MTEC), a biomedical technology consortium working to advance innovative medical solutions to keep military personnel healthy and fully operational.

7/7 2021

Ischemix, Inc. receives US Department of Defense funding of $2.9 million to conduct Phase 1 study of CMX-2043, a novel compound for the treatment of acute TBI

2021-07-07T20:27:53+00:00July 7th, 2021|ATI in the News|

This competitive award was granted by US Army Medical Research and Development Command (USAMRDC), Combat Casualty Care Research Program (CCCRP) in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium.

Go to Top